Core Viewpoint - Emergent BioSolutions Inc. has received a $30 million contract modification from BARDA to supply the CYFENDUS anthrax vaccine, with deliveries expected to start this year and conclude by March 2026 [1][2]. Group 1: Contract Details - The new contract modification is part of an ongoing collaboration with the U.S. government to ensure the availability of medical countermeasures against anthrax [2]. - This follows a previous contract modification of $50 million announced in December 2024 for the same vaccine [3]. Group 2: Product Information - CYFENDUS is indicated for post-exposure prophylaxis of anthrax disease in individuals aged 18 to 65 when administered with recommended antibacterial drugs [4]. - The vaccine was approved by the U.S. FDA in July 2023 for post-exposure use [2]. Group 3: Safety and Efficacy - The efficacy of CYFENDUS for post-exposure prophylaxis is based on studies in animal models of inhalational anthrax [4]. - Important safety information includes contraindications for individuals with a history of severe allergic reactions to the vaccine or its components [5].